Future prospects for the treatment of rapidly evolving viral pathogens: Insights from evolutionary biology

Expert Opinion on Biological Therapy

Volumn 8, Issue 10, 2008, Pages 1455-1460

  Domingo, Esteban ^a   Grande Pérez, Ana ^b   Martín, Verónica ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Antiviral agents; Escape mutants; Fitness landscape; Hepatitis C virus; Human immunodeficiency virus; Lethal mutagenesis; Nucleoside analogs; Quasispecies dynamics; RNA viruses

Indexed keywords

ANTIRETROVIRUS AGENT; MEASLES VACCINE; OSELTAMIVIR; POLIOMYELITIS VACCINE; RIBAVIRIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG DESIGN; DRUG RESPONSE; EVOLUTIONARY ADAPTATION; FOOT AND MOUTH DISEASE VIRUS; GENE REPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS; LETHAL MUTANT; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR EVOLUTION; MUTAGENICITY; NONHUMAN; VIRAL GENETICS; VIRUS INFECTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SURVIVAL; VIRUS VIRULENCE;

ADAPTATION, PHYSIOLOGICAL; EVOLUTION; MUTATION; VIRUSES;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 54349106176     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.10.1455     Document Type: Article

References (40)

1. Knipe D, Howley P, Martin M, et al. Fields virology. 5th edition. Philadelphia: Wolters Kluwer, Lippincott Williams a & Wilkins; 2007
2. Flint S, Enquist L, Krug R, et al. Principles of virology. Molecular biology, pathogenesis and control of animal viruses. 3rd edition. Washington DC: ASM Press; 2009
3. Friedberg EC, Walker GC, Siede W, et al. DNA repair and mutagenesis. Washington DC: American Society for Microbiology; 2006
4. Domingo E, Parrish C, Holland JJ. Origin and evolution of viruses. 2nd edition. Oxford: Elsevier; 2008
5. Batschelet E, Domingo E, Weissmann C. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1976;1:27-32
6. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci USA 1999;96:13910-3
7. Holland JJ, Spindler K, Horodyski F, et al. Rapid evolution of RNA genomes. Science 1982;215:1577-85
8. Domingo E. Virus evolumetion. In: Knipe DM, Howley PM, editors. 5th edition. Fields virology. Lappincott Williams & Wilkins: Philadelphia; 2007 p. 389-421
9. Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathog 2005;1:102-10
10. Vignuzzi M, Stone JK, Arnold JJ, et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 2006;439:344-8
11. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 2008;14:154-61
12. Biebricher CK, Eigen M. What is a quasispecies? Curr Top Microbiol Immunol 2006;299:1-31
13. Eigen M. Viral quasispecies. Sci Am 1993;269:42-9
14. Domingo E, Biebricher C, Eigen M, et al. Quasispecies and RNA virus evolution: principles and consequences. Austin: Landes Bioscience; 2001
15. Holland J. Transitions in understanding of RNA viruses: an historical perspective. Curr Top Microbiol Immunol 2006;299:371-401
16. Martín V, Perales C, Davila M, et al. Viral fitness can influence the repertoire of virus variants selected by antibodies. J Mol Biol 2006;362:44-54
17. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Ann Rev Microbiol 1997;51:151-78
18. Nájera I, Holguín A, Quiñones-Mateu ME, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31
19. Wright S. Evolution in Mendelian populations. Genetics 1931;16:97-159
20. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13:2349-59
21. Quinones-Mateu ME, Moore-Dudley DM, Jegede O, et al. Viral drug resistance and fitness. Adv Pharmacol 2008;56:257-96
22. Sierra M, Airaksinen A, González-López C, et al. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 2007;81:2012-24
23. Ong AK, Hayden FG, John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007;196:181-90
24. Anastassopoulou CG, Marozsan AJ, Matet A, et al. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog 2007;3:e79. Published online 1 June 2007, doi:10.1371/ journal.ppat.0030079
25. Bowen DG, Walker CM. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 2005;42:408-17
26. Peyerl FW, Bazick HS, Newberg MH, et al. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol 2004;78:13901-10
27. Quiñones-Mateu ME, Arts E. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 2006;299:83-140
28. Yeh WW, Cale EM, Jaru-Ampornpan P, et al. Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol 2006;80:8168-77
29. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-1
30. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res 2007;127:131-50
31. Anderson JP, Daifuku R, Loeb LA. Viral error catastrophe by mutagenic nucleosides. Ann Rev Microbiol 2004;58:183-205
32. Domingo E, editor. Virus entry into error catastrophe as a new antiviral strategy. Virus Res 2005;107:115-228
33. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 2002;99:13374-6
34. Graci JD, Cameron CE. Challenges for the development of ribonucleoside analogues as inducers of error catastrophe. Antivir Chem Chemother 2004;15:1-13
35. Ruiz-Jarabo CM, Ly C, Domingo E, et al. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003;308:37-47
36. Grande-Pérez A, Lazaro E, Lowenstein P, et al. Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci USA 2005;102:4448-52
37. Martín V, Grande-Perez A, Domingo E. No evidence of selection for mutational robustness during lethal mutagnesis of lymphocytic choriomeningitis virus. Virology 2008;378:185-92
38. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 2003;100:7289-94
39. Yo NV, Young KC, Lai MMC. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003;42:10462-71
40. Solé RV, Deisboeck TS. An error catastrophe in cancer? J Theor Biol 2004;228:47-54